Bristol-Myers Squibb Company (BMY) 49.46 $BMY
Final Glance: Pharmaceuticals companies
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Early Glance: Pharmaceuticals companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
PR Newswire - Thu Apr 17, 10:30AM CDT
Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use Bayer/Janssen's Xarelto in 14 percent and 31 percent of their patients respectively, with over two-thirds of surveyed physicians increasing their use of Xarelto by 2015. Physicians indicate that Bristol-Myers Squibb/Pfizer's Eliquis is expected to garner a 19 percent patient share in 2015. Use of Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Savaysa are also expected to garner double-digit patient share in 2015, despite the requirement for preceding use of an injectable anticoagulant.
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences ' freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...
2 Reasons Why Merck & Co. Is Crushing the Dow
George Budwell, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
The Dow Jones Industrials has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a...
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate another 79 million are showing symptoms of pre-diabetes . It's a disease with...
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb (BMY) Crosses Pivot Point Resistance at $48.61
Comtex SmarTrend(R) - Wed Apr 16, 10:14AM CDT
Shares of Bristol-Myers Squibb (NYSE:BMY) opened today above their pivot of $48.04 and have already reached the first level of resistance at $48.61. Analysts will be watching for a cross of the next upside pivot targets of $49.04 and $50.04.
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
Business Wire - Wed Apr 16, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
Global Testicular Cancer Drugs Market 2014-2018 with Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
M2 - Wed Apr 16, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7567b6/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer. The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin). Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs. Key vendors dominating this space include: - Bristol-Myers Squibb Co - Hospira Inc. - Teva Pharmaceutical Industries Ltd. - ZIOPHARM Oncology Inc. Other vendors mentioned in the report are: - Baxter International Inc. - Fresenius Kabi Pharmaceuticals Holding Inc. - Mylan Pharmaceutical Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Testicular Cancer by Type - Testicular Cancer Disease by Stages - Treatment Options - Clinical Trial Snapshot - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/75...testicular
How Much Has Merck Shaken Up the Hepatitis C Race?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Even the wildest Gilead bulls seemed to acknowledge that the company was not going to grab and hold 100% share of the hepatitis C (HCV) market. Now the question seems to be shifting to just how much share rivals like AbbVie , Merck , ...
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:30PM CDT
Bristol-Myers is looking to get the once-daily, single tablet fixed-dose combination approved in conjunction with other antiretroviral agents for the treatment of HIV-1 infection.
Portola's Betrixaban Study Design Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:30PM CDT
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.
This Forgotten Pharma Could Be a Hit for Your Portfolio
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 15, 1:30PM CDT
Within the world of Big Pharma, Roche offers a pretty compelling mix. Not only does Roche have one of the strongest oncology platforms today, it also offers one of the deepest pipelines. The company's non-oncology pipeline is not as strong in...
Final Glance: Pharmaceuticals companies
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Early Glance: Pharmaceuticals companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
PR Newswire - Thu Apr 17, 10:30AM CDT
Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use Bayer/Janssen's Xarelto in 14 percent and 31 percent of their patients respectively, with over two-thirds of surveyed physicians increasing their use of Xarelto by 2015. Physicians indicate that Bristol-Myers Squibb/Pfizer's Eliquis is expected to garner a 19 percent patient share in 2015. Use of Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Savaysa are also expected to garner double-digit patient share in 2015, despite the requirement for preceding use of an injectable anticoagulant.
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences ' freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...
2 Reasons Why Merck & Co. Is Crushing the Dow
George Budwell, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
The Dow Jones Industrials has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a...
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate another 79 million are showing symptoms of pre-diabetes . It's a disease with...
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb (BMY) Crosses Pivot Point Resistance at $48.61
Comtex SmarTrend(R) - Wed Apr 16, 10:14AM CDT
Shares of Bristol-Myers Squibb (NYSE:BMY) opened today above their pivot of $48.04 and have already reached the first level of resistance at $48.61. Analysts will be watching for a cross of the next upside pivot targets of $49.04 and $50.04.
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
Business Wire - Wed Apr 16, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
Global Testicular Cancer Drugs Market 2014-2018 with Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
M2 - Wed Apr 16, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7567b6/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer. The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin). Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs. Key vendors dominating this space include: - Bristol-Myers Squibb Co - Hospira Inc. - Teva Pharmaceutical Industries Ltd. - ZIOPHARM Oncology Inc. Other vendors mentioned in the report are: - Baxter International Inc. - Fresenius Kabi Pharmaceuticals Holding Inc. - Mylan Pharmaceutical Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Testicular Cancer by Type - Testicular Cancer Disease by Stages - Treatment Options - Clinical Trial Snapshot - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/75...testicular
How Much Has Merck Shaken Up the Hepatitis C Race?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Even the wildest Gilead bulls seemed to acknowledge that the company was not going to grab and hold 100% share of the hepatitis C (HCV) market. Now the question seems to be shifting to just how much share rivals like AbbVie , Merck , ...
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:30PM CDT
Bristol-Myers is looking to get the once-daily, single tablet fixed-dose combination approved in conjunction with other antiretroviral agents for the treatment of HIV-1 infection.
Portola's Betrixaban Study Design Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:30PM CDT
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.
This Forgotten Pharma Could Be a Hit for Your Portfolio
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 15, 1:30PM CDT
Within the world of Big Pharma, Roche offers a pretty compelling mix. Not only does Roche have one of the strongest oncology platforms today, it also offers one of the deepest pipelines. The company's non-oncology pipeline is not as strong in...
